Brookline Capital Management Increases Veru (NASDAQ:VERU) Price Target to $31.00

Veru (NASDAQ:VERUGet Rating) had its price objective increased by Brookline Capital Management from $29.00 to $31.00 in a report released on Wednesday morning, The Fly reports. They currently have a buy rating on the stock.

Several other brokerages also recently weighed in on VERU. HC Wainwright upped their price target on Veru from $21.00 to $24.00 and gave the stock a buy rating in a report on Tuesday, April 12th. Jefferies Financial Group upped their price target on Veru from $33.00 to $55.00 in a report on Friday, May 13th. Zacks Investment Research downgraded Veru from a buy rating to a hold rating in a report on Thursday, April 21st. Oppenheimer increased their price objective on Veru from $25.00 to $36.00 and gave the company an outperform rating in a report on Tuesday, April 12th. Finally, TheStreet upgraded Veru from a d+ rating to a c rating in a report on Friday, April 29th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $32.17.

Shares of NASDAQ VERU opened at $13.38 on Wednesday. Veru has a twelve month low of $4.34 and a twelve month high of $17.50. The stock has a fifty day simple moving average of $9.08 and a 200-day simple moving average of $7.26. The stock has a market capitalization of $1.07 billion, a PE ratio of -39.35 and a beta of -0.57.

Veru (NASDAQ:VERUGet Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Veru had a negative net margin of 45.56% and a negative return on equity of 18.64%. During the same period last year, the firm earned ($0.04) earnings per share. As a group, analysts expect that Veru will post -0.58 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas grew its stake in Veru by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 12,360 shares of the company’s stock worth $73,000 after buying an additional 2,258 shares during the last quarter. XTX Topco Ltd grew its stake in Veru by 18.7% during the 1st quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock worth $70,000 after buying an additional 2,270 shares during the last quarter. Rhumbline Advisers grew its stake in Veru by 3.6% during the 1st quarter. Rhumbline Advisers now owns 68,654 shares of the company’s stock worth $332,000 after buying an additional 2,410 shares during the last quarter. Swiss National Bank grew its stake in Veru by 2.0% during the 3rd quarter. Swiss National Bank now owns 140,900 shares of the company’s stock worth $1,202,000 after buying an additional 2,700 shares during the last quarter. Finally, Ignite Planners LLC grew its stake in Veru by 7.0% during the 1st quarter. Ignite Planners LLC now owns 45,875 shares of the company’s stock worth $514,000 after buying an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 29.11% of the company’s stock.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Read More

The Fly logo

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.